News & Updates

Patients with radiographic axial spondyloarthritis (r-axSpA) who have been exposed to tumour necrosis factor inhibitor (TNFi) and interleukin (IL)-17 inhibitor (IL-17i) appear to have a lower risk of osteoporosis, but not hip fracture, than biologic disease-modifying antirheumatic drug (bDMARD)-naïve individuals, a recent study has shown.

Individuals with chronic hepatitis D (CHD) may benefit from lonafarnib boosted with ritonavir (LNF/RTV) alone or in combination with peg-interferon-alfa (PEG), findings from the phase III D-LIVR trial have shown.

Treatment with lutikizumab appears to improve outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS) who have not responded to anti-TNF therapy, according to a phase II trial.

Tezepelumab demonstrates steroid-sparing potential in patients with severe asthma, reducing maintenance oral corticosteroid use while maintaining asthma control, as shown in the phase III SUNRISE study.

The use of oral semaglutide does not reduce the speed of clinical progression in individuals with early Alzheimer's disease (AD), according to the results to two phase III trials.

In adult patients with type 2 diabetes (T2D) receiving basal insulin alongside other glucose-lowering medications, real-time continuous glucose monitoring (CGM) demonstrates superiority over self-monitoring of blood glucose (SMBG) in terms of optimizing glycaemic control, according to the FreeDM2 study.

In the treatment of postmenopausal women with moderate-to-severe vasomotor symptoms (VMS), estetrol is well tolerated and helps reduce both the frequency and intensity of symptoms, as shown in the phase III E4COMFORT I study.